<DOC>
	<DOC>NCT00717769</DOC>
	<brief_summary>The purpose of the study is to explore the efficacy and safety of SUN13834 vs placebo in adult subjects with atopic dermatitis</brief_summary>
	<brief_title>A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male or female subjects between 18 and 65 years of age (inclusive). A diagnosis of AD, meeting the Guidelines for Diagnosis of Atopic Dermatitis criteria Taking systemic immunosuppressive drugs or biologicals (within 3 months), or systemic corticosteroids therapy (within 4 weeks)prior to Screening(note: inhaled, intranasal or otic corticosteroids are allowed). Use of phototherapy or tanning beds within 6 weeks of screening History of reactive airway disease (asthma) requiring hospitalization in an intensive care unit in the last 5 years. Presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the Clinical Investigator) that will interfere with interpretation of data from this patient (eg, renal impairment with nonatopic pruritis).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Atopic Dermatitis</keyword>
</DOC>